Trials / Sponsors / Cardurion Pharmaceuticals, Inc.
Cardurion Pharmaceuticals, Inc.
Industry · 11 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Phase 2 Study of CRD-4730 in CPVT Catecholaminergic Polymorphic Ventricular Tachycardia | Phase 2 | 2025-12-01 |
| Completed | Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF) Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases | Phase 2 | 2024-02-13 |
| Completed | A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fracti Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases | Phase 2 | 2024-02-13 |
| Terminated | Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) CPVT1, Heart Defects, Congenital, Heart Diseases | Phase 2 | 2023-11-07 |
| Completed | Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 Clinical Pharmacology, Pharmacokinetics, Cardiovascular Diseases | Phase 1 | 2022-06-27 |
| Terminated | Effectiveness of CRD-740 in Heart Failure Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | Phase 2 | 2022-05-26 |
| Withdrawn | Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction Heart Failure With Preserved Ejection Fraction | Phase 2 | 2022-04-01 |
| Terminated | A Study of IMR-687 in Subjects With Beta Thalassemia β Thalassemia | Phase 2 | 2020-10-16 |
| Terminated | A Study of IMR-687 in Subjects With Sickle Cell Disease Sickle Cell Disease | Phase 2 | 2020-08-13 |
| Completed | A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Sickle Cell Disease | Phase 2 | 2018-01-26 |
| Completed | A Study of IMR-687 in Healthy Adult Volunteers Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia | Phase 1 | 2016-10-18 |